LITS Stock Summary and Trading Ideas (Lite Strategy | NASDAQ:LITS)

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.

Lite Strategy trades on the NASDAQ stock market under the symbol LITS.

As of October 14, 2026, LITS stock price declined to $1.17 with 276,368 million shares trading.

LITS has a beta of 0.90, meaning it tends to be less sensitive to market movements. LITS has a correlation of 0.02 to the broad based SPY ETF.

LITS has a market cap of $35.58 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that LITS belongs to (by Net Assets): VTI, VXF, IWC.

LITS has underperformed the market in the last year with a price return of -45.6% while the SPY ETF gained +17.2%. However, in the short term, LITS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.7% vs +3.0% return in SPY. But in the last 2 weeks, LITS shares have been beat by the market, returning -14.9% compared to an SPY return of +0.7%.

LITS support price is $1.14 and resistance is $1.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LITS shares will trade within this expected range on the day.